MedImmune is the global biologics research and development arm of AstraZeneca and is pioneering innovative research and exploring novel pathways across key therapeutic areas, including oncology; respiratory; and cardiovascular and metabolic disease.
|Address:||Milstein Building, Granta Park , Cambridge|
|Membership type:||Founder Member|
MedImmune is the global biologics research and development arm of AstraZeneca with candidate biologics and vaccines that currently compromise approximately 50 per cent of AstraZeneca’s overall R&D pipeline. It has one of the most robust and promising pipelines in the biologics industry, with more than 120 biologics in research and development and over 40 projects in clinical stage development.
MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas, including oncology; respiratory; and cardiovascular and metabolic disease. In addition, the company is opportunistic in infectious disease and vaccines. Approximately 2,200 full-time employees are in the US and UK. MedImmune is headquartered in Gaithersburg, MD – one of AstraZeneca’s three global R&D centres, along with Cambridge, UK and MoIndal, Sweden
MedImmune’s Cambridge team is focused on the research and early development of our biologics portfolio. MedImmune has built on the local legacy of Cambridge Antibody Technology (CAT) – acquired by AstraZeneca and integrated with MedImmune in 2007 – where three marketed products (Humira, Benlysta and raxibacumab) were invented. With over 600 employees, MedImmune Cambridge has strong collaborative links with numerous academics, researchers, foundations and neighbouring companies in the largest biotech cluster in Europe and has an active outreach programme within the local community.
1 Humira is a registered trademark of AbbVie Inc.
2 Benlysta is a registered trademark of GlaxoSmithKline
MedImmune is the global biologics research and development arm of AstraZeneca, focused on pioneering research and exploring novel mechanisms and pathways across key therapeutic areas.
MedImmune today announced that its corporate brand will be retired as biologics are integrated into AstraZeneca’s two new research and development units.
14 February 2019Read in full
MedImmune, the global biologics research and development arm of AstraZeneca, and Cambridge Network recently hosted the first Cambridge Digital Health Forum. The event brought together over 130 delegates from industry and academia to explore how digital technologies could potentially make a significant positive impact on patients with respiratory diseases.
11 May 2018Read in full
MedImmune, the global biologics research and development arm of AstraZeneca, and University Technical College (UTC) Cambridge have completed an eight-week ‘Challenge Project’ for 45 Year Ten students, focused on exposing students to the multifaceted processes involved in delivering new biological medicines to patients with high unmet needs.
25 May 2017Read in full
It’s a challenge – making sure that AstraZeneca lands at its new Cambridge headquarters in a sympathetic way to the community. In the latest Cambridge Network Founder interview, Jane Osbourn, Vice President of R&D and Site Leader in Cambridge for MedImmune, the global biologics research and development arm of AstraZeneca, talks about the opportunities presented by the move to the Cambridge Biomedical Campus later this year.
7 March 2017Read in full
MedImmune, the global biologics research and development arm of AstraZeneca, and a consortium of universities — the Universities of Cambridge, Leeds, Manchester and Sheffield—today announced they will be afforded a Collaborative Training Partnership (CTP), structured as 12 PhD studentships, from the Biotechnology and Biological Sciences Research Council (BBSRC).
30 November 2016Read in full
AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a licensing agreement with Allergan plc for the global rights to MEDI2070, a potential medicine for inflammatory diseases.
3 October 2016Read in full
AstraZeneca has announced that its global biologics research and development arm, MedImmune, has received Fast Track designation from the US Food and Drug Administration (FDA) for its investigational human monoclonal antibody (mAb), MEDI8852, for the treatment of patients hospitalised with Type A strain influenza.
9 March 2016Read in full
MedImmune, the global biologics research and development arm of AstraZeneca, and 3M Drug Delivery Systems have announced a research collaboration focused on developing next generation toll-like receptor (TLR) agonists - promising agents that activate innate immune cells and enhance the visibility of cancer tumors.
28 September 2015Read in full
MedImmune, the global biologics research and development arm of AstraZeneca, and Tanabe Research Laboratories U.S.A., Inc. (TRL), a subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC), today announced that they have entered into a strategic collaboration and licensing agreement under which TRL will use MedImmune’s pyrrolobenzodiazepine (PBD)-based warhead and linker technology to generate monospecific and bispecific antibody-drug conjugates (ADCs) for investigation in various cancers.
25 September 2015Read in full